Our research centers on understanding cell signaling events that regulate the development of disease caused by intracellular pathogens and the development of inflammatory disorders of importance in humans. Translational approaches are currently being pursued to identify novel and improved therapeutic approaches against these diseases.
Identification of the molecular events by which the intracellular pathogen Toxoplasma gondii activates cell signaling in host cells to prevent autophagic degradation of the parasite.
Study the role of CD40-TRAF signaling in promoting various events critical to de development of diabetic retinopathy.
Study the role of CD40-TRAF signaling in Inflammatory Bowel Disease.
NEWS and Press Releases
NEWS | C-Path’s Translational Therapeutics Accelerator Announces $200,000 Grant for Drug Development Project in Inflammatory Bowel Disease
Critical Path Institute’s C-Path Translational Therapeutics Accelerator proudly announced today a $200,000 grant to Carlos Subauste, M.D., an internist and infectious disease specialist at University Hospitals Cleveland Medical Center Inc. and professor at Case Western Reserve University, to advance a promising new therapy for inflammatory bowel disease.
IBD — a chronic and often debilitating condition affecting more than 2.4 million Americans, with approximately 70,000 new diagnoses each year — causes ongoing inflammation of the gastrointestinal tract, resulting in severe abdominal pain, weight loss, and irreversible damage to intestinal tissue.
Read the full press release here: https://lnkd.in/eZmx4EBA